Theisen said that this discovery provides new pathways for autoimmune treatments that target Granzyme K. “There are plenty of inhibitors and treatments targeting the complement cascade ...

Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular ...